Project Grant R01HL181967
Award Date 8/14/26
Completion Date 4/30/30
Dollars Obligated $817K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University a Project Grant (K99HL181309) of $129,600 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize a novel mechanism of atherosclerosis development. The funded research investigates digestive exophagy, a process by which macrophages form extracellular, acidic compartments to hydrolyze aggregated low-density lipoprotein that is bound to the extracellular...
- The National Heart, Lung, and Blood Institute awarded New York University $737,762 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation and its role in ischemia with nonobstructive coronary arteries (INOCA). The research examines coronary microvascular dysfunction as a key mechanism in INOCA, a chronic disorder characterized by angina, dyspnea, physical limitation, and impaired quality of life. The project directly harvests...
- The National Heart, Lung, and Blood Institute awarded Albany Medical College $1,634,428 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate inflammation-resolution mechanisms in endothelial cells as they relate to atherosclerosis progression and regression. The project addresses a gap in understanding how pro-resolving mediators—including specialized pro-resolving mediators derived from omega-3 fatty acids (such as resolvins), suppressor of cytokine...
- The National Heart, Lung, and Blood Institute awarded Albany Medical College $586,474 under CFDA 93.837 (Cardiovascular Diseases Research) on June 15, 2026, to investigate lipolytic sterol signaling mechanisms in foam cell modulation and atherosclerosis prevention. The project targets lipid droplet-associated hydrolase (LDAH) as a regulator of adaptive responses to lipid overload in atherosclerotic lesions. Research will examine how LDAH mobilizes sterol stores within cytoplasmic lipid...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,500 on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage biology in atherosclerosis and atherosclerosis-related cardiometabolic disease. The award funds a comprehensive program exploring the role of macrophage efferocytosis and resolution cycles in promoting fibrous cap thickening in atherosclerotic plaques and...
- The National Heart, Lung, and Blood Institute awarded New York University's Long Island School of Medicine $2.728 million on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on reducing plasma cholesterol and atherosclerosis using C2, a synthetic microRNA-30c analog. The research will elucidate molecular mechanisms by which C2 administration reduces plasma cholesterol levels in mice with diet-induced hypercholesterolemia and LDL receptor...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $768,414 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic profiling research examining the relationship between idiopathic pulmonary fibrosis and cardiovascular disease. The research identifies shared molecular mechanisms linking pulmonary fibrosis and cardiovascular disease through blood-based and tissue analysis. The project defines shared...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $818,022 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize endothelin-1 (ET-1) and its receptor (ET-RA) as cardiomyocyte proliferation inhibitors in neonatal mice. The research aims to identify mechanisms by which extracellular inhibitory factors suppress heart cell proliferation, with the long-term goal of enabling therapeutic strategies to...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded New York University $763,960 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which long non-coding RNA IRF1-AS1 and its mouse ortholog GM12216 regulate atherosclerotic cardiovascular disease. The research will examine how IRF1-AS1 coordinates expression of protein-coding genes including the transcriptional regulator IRF1 in myeloid cells to drive atherogenesis,...